Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-02-13
1998-01-06
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514425, 514426, 548952, 435 692, 562553, 562577, 562582, A01N 4336, C07D20510, C12P 2102, C07C20928
Patent
active
057055220
ABSTRACT:
A new family of compounds having anti-inflammatory, anti-viral, and brocho-dilating activity having the following linear and cyclic formulas: ##STR1## and compositions of these, which alone, and in combination with reverse transcriptase inhibitors thereby resulting in an additive or synergistic effect, are useful in inhibiting or suppressing viruses including those exhibiting retroviral replication, or in treating viruses including a retrovirus such as HIV in a human cell population and methods of using these compositions, compounds, and salts thereof.
REFERENCES:
patent: 4861759 (1989-08-01), Mitsuya et al.
patent: 5254539 (1993-10-01), Mitsuya et al.
patent: 5571839 (1996-11-01), Vila et al.
PCT/ISA/220 Notification of Transmittal of the International Search Report or Declaration dated Dec. 18, 1996.
International Search Report dated Dec. 10, 1996.
Blodgett, et al., "Specific Cleavage of Peptides Containing an Aspartic Acid (.beta.-hydroxamic Acid)", J. Am. Chem. Soc., 1985, 107, 4305-4313.
J. Org. Chem., vol., 42, No. 10, (1977), pp. 1750-1761, Miller et al., "The Chemistry of a Method for the Determination of Carboxyl-Terminal Residues in Peptide".
J. Am Chem. Soc. 1985, vol. 107, pp. 4305-4313 "Specific Cleavage of Peptides Containing an Aspartic Acid (.beta.-Hydroxamic Acid) Residue", Blodgett et al.
CDC (Center for Disease Control), MMWR, 30: 305-308.DC, (1981).
Barre-Sinoussi F. et al., Science, 220: 868-870 (1983).
Fauci AS., Science, 239, 617-622, (1988).
Fauci AS., Science, 262: 1011-1018. (1993).
Zack J.A. et al., Cell, 61, 213-222, (1990).
Bukrinsky M.I. et al,; Science, 254, 423-427, (1991).
Schnittman S M. et al., Science, 245, 305-308, (1989).
Fox CH. et al., J. Infect Dis; 164, 1051-1057, (1991).
Hirsch MS, et al., New Engl. J. Med. 328, 1686-1695, (1993).
Pauwels, R. et al., J. Virol. Methods, 20, 309-321 (1988).
Yarchoan et al., New Engl J. Med, 321, 726-738 (1989).
Chow et al., Nature, 361, 650-654 (1993).
Lori et al., Science, 266: 801-805 (1994).
McMillan R., et al, TIPS, Aug. 1992, vol. 13, pp. 323-330.
Merck Index 10, 8741, 8744, 8745, (1983).
M. Bodansky, A. Bodansky, The Practice of Peptide Synthesis, 125 (1984).
Vogel, Text-Book of Practical Organic Chemistry, 371, 375-377 and 840, (3rd. edition, 1957).
Grange Jacques
Hamedi-Sangsari Farid
Nugier Fabienne
Vallet Thierry
Vila Jorge
Compagnie de Developpement Aguettant S.A.
Oswecki Jane C.
Richter Johann
LandOfFree
Compounds having anti-inflammatory and anti-viral activity, comp does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds having anti-inflammatory and anti-viral activity, comp, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds having anti-inflammatory and anti-viral activity, comp will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2329474